The cost of chemotherapy-induced nausea and vomiting in Italy

Supportive Care in Cancer

Volumn 15, Issue 1, 2007, Pages 31-38

  Ballatori, Enzo ^a   Roila, Fausto ^b   Ruggeri, Benedetta ^c   Porrozzi, Stella ^b   Iannopollo, Mauro ^d   Soru, Giancarla ^e   Cruciani, Giorgio ^f   Daniele, Bruno ^g   Locatelli, Maria Cristina ^h   Pellissier, James ⁱ   Deuson, Robert ⁱ  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Medical Oncology Division   (Italy)

^c ASUR ^*  (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e SS Annunziata Hospital   (Italy)

^f Ospedale Civile   (Italy)

^g G RUMMO HOSPITAL   (Italy)

^h SAN CARLO BORROMEO HOSPITAL   (Italy)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chemotherapy induced nausea and vomiting; Cost of illness; Health economics; Healthcare utilization; Pharmacoeconomics

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; FLUOROURACIL; GEMCITABINE; METOCLOPRAMIDE; SEROTONIN 3 ANTAGONIST;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; FEMALE; GOVERNMENT; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL COST; HOSPITAL PHARMACY; HUMAN; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; NATIONAL HEALTH SERVICE; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; COST OF ILLNESS; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; NAUSEA; OBSERVATION; PROSPECTIVE STUDIES; STATE MEDICINE; VOMITING;

EID: 33846155877     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0094-x     Document Type: Article

References (16)

1. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 9:811-819
2. Ballatori E, Roila F, Berto P, De Angelis V, Neri C, Olivieri A, Tonato M, Del Favero A (1994) Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy. Pharmacoeconomics 5:227-237
3. Berard CM, Mahoney CD (1995) Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting. Am J Health Syst Pharm 52:1879-1885
4. Crawford J, Dale DC, lyman GH (2004) Chemotherapy-induced neutropenia. Risks, consequences, and new directions for its management. Cancer 100:228-237
5. de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, von Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055-1061
6. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003) The burden of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531-1539
7. Gralla RJ, Osoba D, Kris MG, Kirkbride O, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol 17:2971-2994
8. Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis in cancer patients. N Engl J Med 329:1790-1796
9. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261-2268
10. Ihbe-Heffinger A, Ehlken B, Bernard R et al (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526-536
11. Italian Group for Antiemetic Research (1997) Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 15:124-130
12. Italian Group for Antiemetic Research (1999) Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Support Care Cancer 8:229-232
13. Koeller JM, Aapro MS, Gralla RJ, Grunberg SM, Hesketh PJ, Kris MG, Clark-Snow RA (2002) Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 10:519-522
14. O'Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F (1993) Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ 149:296-302
15. Stewart DJ, Dahrouge S, Coyle D, Evans WK (1999) Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol 17:344-351
16. Uyl-de Groot CA, Wait S, Buijt I (2000) Economics and health-related quality of life in antiemetic therapy: recommendations for trial design. Eur J Cancer 36:1522-1535